Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
 ««+1  ««-1
 
 
Glenmark Pharmaceuticals LtdIndustry : Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code:532296NSE Symbol: GLENMARKP/E(TTM):31.39
ISIN Demat:INE935A01035Div & Yield %:0.12EPS(TTM):66.4
Book Value(Rs):868.316327Market Cap ( Cr.):58827.58Face Value(Rs):1
    Change Company 
( In Cr)
 Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
INCOME :      
Sales Turnover 9226.417891.128220.668141.587567.936712.63
Excise Duty0.000.000.000.000.000.00
Net Sales9226.417891.128220.668141.587567.936712.63
Other Income 356.376238.36985.941044.96470.13625.34
Stock Adjustments -44.48103.0731.3716.13-5.24-48.77
Total Income9538.3014232.559237.979202.678032.827289.20
EXPENDITURE :      
Raw Materials 3154.653313.193427.073474.662944.532617.22
Power & Fuel Cost114.62104.9295.0991.3480.4990.76
Employee Cost 1603.501434.781346.511193.201107.401072.33
Other Manufacturing Expenses 372.36375.32304.66297.44267.26230.03
Selling and Administration Expenses 1305.301199.171246.101062.89914.37977.77
Miscellaneous Expenses 566.49325.15855.71349.97358.30371.53
Less: Pre-operative Expenses Capitalised0.000.000.000.000.000.00
Total Expenditure7116.926752.527275.136469.505672.355359.63
Operating Profit2421.387480.021962.842733.182360.471929.57
Interest 48.73277.11206.82236.04265.90256.39
Gross Profit2372.657202.911756.022497.142094.571673.18
Depreciation218.63202.16184.15159.70150.82138.54
Profit Before Tax2154.027000.751571.872337.441943.751534.64
Tax316.091049.99386.93411.08343.62269.24
Fringe Benefit tax0.000.000.000.000.000.00
Deferred Tax227.58783.46-23.83-71.42-49.31-89.14
Reported Net Profit1610.355167.291208.771997.791649.451354.55
Extraordinary Items -133.983742.26-369.56354.0259.8714.43
Adjusted Net Profit1744.331425.031578.331643.771589.581340.12
Adjst. below Net Profit -6.47-4.760.631.612.48-5.42
P & L Balance brought forward21088.1316002.8214863.9612921.8611340.4710059.38
Statutory Appropriations 0.000.000.000.000.000.00
Appropriations 110.8777.2270.5457.3070.5468.03
P & L Balance carried down22581.1521088.1316002.8214863.9612921.8611340.47
Dividend0.000.000.000.000.000.00
Preference Dividend0.000.000.000.000.000.00
Equity Dividend %250.00250.00250.00250.00250.00250.00
Earnings Per Share-Unit Curr57.07183.1142.8470.8058.4648.00
Earnings Per Share(Adj)-Unit Curr57.07183.1142.8470.8058.4648.00
Book Value-Unit Curr868.35814.01633.57593.21524.84468.73